As of 2021, there is no cure for<unk>  other than strict avoidance of<unk> s and<unk> -containing foods. Extra care is needed for food consumed at or purchased from restaurants. Total avoidance is complicated because the declaration of the presence of trace amounts of allergens in foods is not mandatory (see regulation of labelling). Immunotherapy Immunotherapy involves attempts to reduce allergic sensitivity by repeated exposure to small amounts of<unk>  products. Evidence as of 2019, however, has found that it increases rather than decreases the risk of serious allergies. None of these are considered ready for use in people outside of carefully conducted trials. A 2012 Cochrane Review concluded that more research was needed. Sublingual immunotherapy involves putting gradually increasing doses of an allergy extract under a person's tongue. The extract is then either spat or swallowed. As of 2014, the evidence did not show that this was safe or effective. Epicutaneous immunotherapy involves giving the allergen through a patch and has also been researched. In September 2014, the U.S. Food and Drug Administration (FDA) granted fast track designation, and in June 2015, granted breakthrough therapy designation to AR101 for<unk>  in ages 4–17. AR101 was studied in the PALISADE international, multicenter, randomized, double-blind, placebo-controlled study. In September 2019, the Allergenic Products Advisory Committee (APAC) of the Center for Biologics Evaluation and Research (CBER) voted to support the use of<unk> n powder (Palforzia) for<unk> . The price has not been set as of September 2019, but is proposed to be between and per year. In January 2020,<unk> n powder was approved in the United States to mitigate allergic reactions, including anaphylaxis, that may occur with accidental exposure to<unk> s. Treatment with<unk> n powder may be initiated in individuals ages four through 17 years with a confirmed diagnosis of<unk>  and may be continued in individuals four years of age and older. Those who take<unk> n powder must continue to avoid<unk> s in their diets. On 15 October 2020, the European Medicines Agency (EMA) issued a favourable opinion for a medicinal product made from defatted powder of Arachis hypogaea. This medicine will be available as an oral powder in capsules (0.5, 1, 10, 20 and 100 mg) and as an oral powder in sachets (300 mg).
Peanut allergy
Tree nut allergy
Corn allergy
Fruit allergy
Sesame allergy
Rice allergy
Shellfish allergy
Insect sting allergy